The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study
暂无分享,去创建一个
Samy Suissa | Laurent Azoulay | Kristian B Filion | S. Suissa | M. Pollak | K. Filion | Hui Yin | Jonathan Assayag | Agnieszka Majdan | Michael N Pollak | L. Azoulay | Jonathan Assayag | H. Yin | A. Majdan
[1] R. Breyer,et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. , 1999, Neoplasia.
[2] G M Leydon,et al. Validation of the diagnosis of venous thromboembolism in general practice database studies. , 2000, British journal of clinical pharmacology.
[3] T. Walley,et al. The UK General Practice Research Database , 1997, The Lancet.
[4] L. G. García Rodríguez,et al. Use of the UK General Practice Research Database for pharmacoepidemiology. , 1998, British journal of clinical pharmacology.
[5] H Jick,et al. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. , 1991, BMJ.
[6] R. Lawrenson,et al. Clinical information for research; the use of general practice databases. , 1999, Journal of public health medicine.
[7] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[8] Y. Kawahito,et al. Expression of peroxisome proliferator‐activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists , 2003, International journal of cancer.
[9] S. Larsson,et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis , 2006, Diabetologia.
[10] M. L. Bruin,et al. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data , 2012, Diabetologia.
[11] H. Kandori,et al. Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. , 2011, Toxicology and applied pharmacology.
[12] W. Bilker,et al. Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone , 2011, Diabetes Care.
[13] S. Benoit,et al. Predictors of glycemic control among patients with Type 2 diabetes: A longitudinal study , 2005, BMC public health.
[14] K. Hattori,et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. , 2001, The American journal of pathology.
[15] Elisabetta Poluzzi,et al. Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting , 2011, Diabetes Care.
[16] Samy Suissa,et al. The nested case-control study in cardiology. , 2003, American heart journal.
[17] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[18] S. Suissa. Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis , 2002 .
[19] E. Oetjen. Antidiabetic actions of a non–agonist PPARγ ligand blocking Cdk5–mediated phosphorylation , 2012 .
[20] E. Wilkinson. Cancer Research UK , 2002 .
[21] B. Kahn,et al. Rosiglitazone, PPARγ, and type 2 diabetes. , 2010, The New England journal of medicine.
[22] Michal Abrahamowicz,et al. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure , 2005 .
[23] M. Cano,et al. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action. , 2006, Toxicologic pathology.
[24] Corri Black,et al. Validity of the General Practice Research Database , 2003, Pharmacotherapy.
[25] E. Ward,et al. Royal Colleges must act over Health and Social Care Bill , 2011, The Lancet.
[26] W. Ray,et al. Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.
[27] Samuel M. Cohen,et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[28] M. Lai,et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus , 2012, Hepatology.
[29] A. Lincoff,et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.
[30] A. Ferrara,et al. Diabetes and risk of bladder cancer , 2011, Cancer.
[31] Scott A. Busby,et al. Anti-Diabetic Actions of a Non-Agonist PPARγ Ligand Blocking Cdk5-Mediated Phosphorylation , 2011, Nature.
[32] R. Breyer,et al. Expression of Peroxisome Proferator-Activated Receptor γ (PPARγ) in Human Transitional Bladder Cancer and its Role in Inducing Cell Death , 1999 .
[33] Samuel M. Cohen,et al. Urothelial Carcinogenesis in the Urinary Bladder of Male Rats Treated with Muraglitazar, a PPARα/γ Agonist: Evidence for Urolithiasis as the Inciting Event in the Mode of Action , 2006, Toxicologic pathology.
[34] R. Perera,et al. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases , 2010, BMC family practice.
[35] Krystal L. Edwards,et al. Third‐Line Agent Selection for Patients with Type 2 Diabetes Mellitus Uncontrolled with Sulfonylureas and Metformin , 2008, Pharmacotherapy.